Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Alx Oncology Holdings Inc (ALXO)

Alx Oncology Holdings Inc (ALXO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Why ALX Oncology Stock Is Skyrocketing Today Motley Fool - Tue Oct 3, 2023

Investors are cheering the immuno-oncology company's latest clinical trial results.

ALXO : 8.13 (+1.63%)
Wall Street - shutterstock_1321462394
Stock Index Futures Plunge Ahead of U.S. JOLTs Report, U.S. Rates Stay in Focus Barchart - Tue Oct 3, 2023

December S&P 500 futures (ESZ23) are down -0.38%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.50% this morning as market participants looked ahead to the release of fresh labor market data...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
NVDA : 126.36 (-1.62%)
META : 489.79 (-1.28%)
GOOGL : 183.92 (-1.40%)
PODD : 201.39 (+1.27%)
K : 57.05 (+1.30%)
TGT : 155.01 (+2.45%)
BOO.LN : 35.000 (+0.34%)
ZAL.D.DX : 24.510 (-0.08%)
ALXO : 8.13 (+1.63%)
ODD : 44.24 (+2.69%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation Investor Brand Network - Thu Sep 21, 2023

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

GNPX : 2.0600 (+4.04%)
RHHBY : 36.2700 (+0.86%)
JAZZ : 106.09 (+2.67%)
ALXO : 8.13 (+1.63%)
ACHL : 0.8579 (+2.26%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation Investor Brand Network - Wed Sep 20, 2023

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

GNPX : 2.0600 (+4.04%)
RHHBY : 36.2700 (+0.86%)
JAZZ : 106.09 (+2.67%)
ALXO : 8.13 (+1.63%)
ACHL : 0.8579 (+2.26%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation FinancialNewsMedia - Wed Sep 20, 2023

EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END

GNPX : 2.0600 (+4.04%)
RHHBY : 36.2700 (+0.86%)
JAZZ : 106.09 (+2.67%)
ALXO : 8.13 (+1.63%)
ACHL : 0.8579 (+2.26%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation PR Newswire - Wed Sep 20, 2023

/PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the...

RHHBY : 36.2700 (+0.86%)
GNPX : 2.0600 (+4.04%)
JAZZ : 106.09 (+2.67%)
ALXO : 8.13 (+1.63%)
ACHL : 0.8579 (+2.26%)
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer Globe Newswire - Thu Aug 11, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage...

ALXO : 8.13 (+1.63%)
ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights Globe Newswire - Mon Aug 8, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage...

ALXO : 8.13 (+1.63%)
ALX Oncology’s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma Globe Newswire - Mon Aug 1, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage...

ALXO : 8.13 (+1.63%)
Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors Business Wire - Thu Jul 28, 2022

Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced that the first patient has been dosed with TAC-001...

ALXO : 8.13 (+1.63%)

Barchart Exclusives

2 Underperforming Dividend Stocks With Strong Brands and Over 20% Upside Potential Barchart - Tue Jul 16, 6:30PM CDT
Nike and Starbucks both offer a dividend yield that's higher than the S&P 500 Index. Both stocks have fallen sharply from their peaks, and analysts see decent upside from these levels. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot